Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at kombinationen af en opioid analog og en opioidantagonist er en etableret strategi til reducering af risikoen for intravenøst misbrug.
The Committee for Medicinal products for Human Use (CHMP) concluded that the combination of an opioid analogue with an opioid antagonist is an established strategy for reducing the potential for intravenous misuse.